Dr Yugarajah Asokumaran completed his undergraduate medical training at Universiti Sains Malaysia in 2007. He then obtained his MRCP in 2014 and subsequently underwent training in Medical Oncology in National Cancer Institute Singapore 2018 to 2021. He is recipient Excellent Service Award 2014 by Ministry of Health Malaysia and Shine Awards by National University Health System Singapore 2020. Dr Yuga treats a broad range of solid tumour such as Lung Cancers, Breast cancers, gastrointestinal cancers, genitourinary cancers, head and neck cancers, gynaecological cancer and sarcoma. He is experienced in cancer survivorship issues such as surveillance and coordinating rehabilitation post completion of treatment. He is a Co-Investigator for multiple phase 2 and phase 3 clinical trials in Singapore prior to his return to Malaysia. He served as a Medical Oncologist in Advanced Medical and Dental Institute, USM Penang before joining Thomson Hospital as a Medical Oncologist.
1. Pericardial effusion in pregnancy; two case reports and a discussion. Asokumaran et al 2015 presented at 9th Asia Pacific Cardiology Update
2. Multiple Intracranial Tuberculoma; a case report and discussion. Asokumaran et al presented at Selangor Research Day 2015
3. Early experience of Immune checkpoint inhibitors in renal cell carcinoma NUH. 5th NCIS Annual Research Meeting 2018. Matilda Lee , Yugarajah Asokumaran , Gloria Chan , Natalie Ngoi , Joan Choo , Vaishnavi Muthu , Huang YQ , Barr Kumarakulasinghe Nesaretnam , Goh Boon Cher , Yong Wei Ping , Balamurugan A , Leong Cheng Nang , Thian Yee Liang , Alvin SC Wong , presented at 5th NCIS Annual Research Meeting 2018
4. A Single Centre Experience Of Genetic Testing In Ovarian Cancer; Utilisation and therapeutic implication . NCAM Annual research meeting 2019Yugarajah A , Pei Yi Ong, Jeffrey JH Low, Joseph SY Ng, Samuel Guan Wei Ow , David SP Tan , Yi Wan Lim , Lim Siew Eng , Soo Chin Lee
5. The role of targeted therapy in treatment of advanced hepatocellular carcinoma in the era of immunotherapy: Real-world data using AI analytics from an academic medical center. Rachel Su Jen Wong, Jiaxuan Wu, Alisha Joan Leen, Glenn Jin Chong Tey, Yugarajah Asokumaran, Gloria Chan, Chidambaram Siddappan, Anand Devaprasath Jeyasekharan, Cheng Ean Chee, Wei-Peng Yong, Kee Yuan Ngiam, and Raghav Sundar Journal of Clinical Oncology 2020 38:15_suppl, e16623-e16623
6. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma. ASCO 2021 JCO 38 2020 . Robert John Walsh, Emily Pauline Nickles, Yating Li, Bhushan Dharmadhikari, Mickey Koh, Liam Pock Ho, Marieta Chan, Liang Piu Koh, Michelle Li Mei Poon, Lip Kun Tan, Yiqing Huang, Yvonne Li’en Ang, Wan Qin Chong, Yugarajah Asokumaran, Kwok Seng Loh, Ross A. Soo, Chwee Ming Lim, Herbert Schwarz, Boon Cher Goh
7. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsNavigating the Radiologic Potpourri. 2021 Apr 2;13(7):1689. doi: 10.3390/cancers13071689. PMID: 33918397; PMCID: PMC8038243. Wong A, Vellayappan B, Cheng L, Zhao JJ, Muthu V, Asokumaran Yugarajah , Low JL, Lee M, Huang YQ, Kumarakulasinghe NB, Ngoi N, Leong CN, Chua W, Thian YL
8. Real-work Experience of consolidation durvalumab after concurrent radiotherapy in stage III non-small cell lung cancer 2022 Jun Thoracic Cancer. 13. 10.1111/1759-7714.14667. Huang Yiqing , Zhao Joseph, Soon Yu Yang, Wong, Alvin Wong, Aminkeng Folefac ,Yvonne Ang, Asokumaran Yugarajah, Low Jia Li, Lee Matilda, Joan Choo, Gloria Chan, Adrian Kee, Tay Sen, Goh Boon Cher & Ross Soo
9. Nickles, E., Dharmadhikari, B., Yating, L. Yugarajah Asokumaran et al. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit. Cancer Immunol Immunother 71, 1531–1543 (2022)
10. Choon Seong Ang, …Yugarajah Asokumaran et al Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.. JCO 40, 3584 3584(2022). DOI:10.1200/JCO.2022.40.16_suppl.3584
11. Qin Jian Low, Joseph J.Zhao, Racehl Su Jen Wong, Yugarajah Asokumaran et al MO34-4 Advanced Hepatocellular carcinoma viral status and immunotherapy efficacy: A propensityscore matched analysis Annals of Oncology 2023, https://doi.org/10.1016/j.annonc2023.09.240
12. Jia Li Low, Yugarajah Asokumaran et alCost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lun g cancer patients in Asia. JCO 38, e19385-e19385(202) DOI:10.1200/JCO.2020.38.15 suppl.e19385
Clinical fellowship in Medical Oncology (National Cancer Institute Singapore)
- MOS (Malaysian Oncological Society)
- ESMO (European Society of Medical Oncology)
- ASCO (American Society of Clinical Oncology)
Head and Neck Cancer Clinical Trials
- Dendritic cell therapy with CD137L-DC-EBV-VAX in locally advanced stage IV locally recurrent/metastatic Nasopharyngeal Carcinoma
Role : Co-Investigator
Place : National Cancer Institute Singapore
- Phase 1b/11 open label study evaluating the combination of bevacizumab priming with pembrolizumab in EBER-ISH positive Nasopharyngeal carcinoma
Role: Co-Investigator
Place: National Cancer Institute Singapore
- Nivolumab in combination with chemoradiation for patients with stage II-IVb Nasopharyngeal carcinoma, A phase II study
Role: Co-Investigator
Place: National Cancer Institute Singapore
- A phase 2 study of ALX148 in combination with Pembrolizumab in Patients with Advanced Head and NECK Squamous Cell Carcinoma (ASPEN03)
Role: Co-Investigator
Place: National Cancer Institute Singapore
- A Phase II randomized trial of induction cisplatin and gemcitabine and vs Cisplatin, Gemcitabine, Bevacizumab and Pembrolizumab in Nasopharyngeal Cancer
Role: Co-Investigator
Place: National Cancer Institute Singapore Breast Cancer Clinical Trials
- Phase II ASLAN001 combined with weekly paclitaxel and Herceptin in HER2 positive stage 1-3 breast cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- Phase II, Single Arm, Open Label, Simon Two-Stage Study of pembrolizumab in metastatic HER 2 negative breast cancer patients:evaluation of impact of germline variants in APOBEC3B (AUROR)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase 3, Randomized, Multi-Center, Open-Label Study of Trastuzumab Deruxtecan vs Investigators Choice of Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose disease has progressed on Endocrine Therapy in the Metastatic Setting (DestinyBreast06)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive HER2 negative breast cancer, who have progressed on CDK 4.6 inhibitors (ELEVATE)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- EPIK-B4: A Phase II, multicenter, randomized open label, active-controlled study to assess the safety and efficacy of dapagliflozin +metformin XR versus metformin during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER 2-, advanced breast cancer with PIK#CA mutation following progression on/after endocrine-based therapy
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A randomized, multicenter, Double Blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant chemotherapy and Adjuvant Endocrine Therapy in Patients with High risk, Estrogen Receptor-Positive(ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER 2 -) Primary Breast Cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase II, randomized, open label, multicenter study evaluating the efficacy and safety of GDC9545 compared with Physician’s Choice of Endocrine Monotherapy in Patients with Previously treated with Estrogen Receptor-Positive, HER 2 negative Locally advanced or metastatic breast cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with adotrastuzumab emtansine(T-DM1) for subjects with unresectable locally -advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)
Role : Co-Investigator
Place : National Cancer Institute Singapore
Lung Cancer Clinical Trials
- Improvement in the value of orally administered cancer drugs: Osimertinib for advanced EGFRpositive NSCLCL patients-a phase II study
Role : Co-Investigator
Place : National Cancer Institute Singapore
- HERTHENA-Lung01, a Phase II Trial of PAtritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Caner after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A phase Ib Multicenter, Open-Label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecanand Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-Line treatment of patients with advanced or metastatic non squamous Non Small Cell Lung Caner and HER2 Over expression ( Destiny-Lung 03)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A phase1b/2 study to evaluate the combination of nivolumab (anti PD1 monoclonal Ab) with ADG106 (4-1 BB agonist monoclonal Ab) in metastatic NSCLC after progression with anti PD1 therapy and platinum-based chemotherapy ( ADIVO Lung Study )
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A phase 1/2a Study of BMS-986207 Monoclonal Antibody-alone and in Combination with Nivolumab and Ipilimumab in Advanced Solid Tumors
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase III Randomized, Multicenter, Double-Blind, Placebo-controlled Study of Durvalumab for the treatmentof Stage II-III NSCLC patients with Minimal Residual Disease Following Surgery and Curative Intent therapy ( MERMAID-2)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase 1b, open label, multi-center study to characterize the safety, tolerability and preliminary efficacy of EGF816 in combination with selected targeted agents in EGFR mutant
NSCLC Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase I/II, Randomized, Double-Blind, Placebo-Controlled study of Carboplatin Plus Etoposide Plus Atezolizumab With or Without Tiragolumab (anti-TIGIT antibody) in patients with untreated Extensive-Stage Small Cell Lung Cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase III, randomized , Double-Blind Study to Assess the Efficacy and safety of Lazertinib versus Gefitinib as First Line Treatment in Patients with Epidermal Growth Factoir Receptor Sensitizing Mutation positive, Locally advanced or metastatic non-small cell lung cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-tumor activity of TPX-0005 in patients with Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT )
Role : Co-Investigator
Place : National Cancer Institute Singapore
Gastrointestinal and Hepatobiliary cancer Clinical Trials
- A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in subjects with HER2-positive Metastatic and/or Unresectable Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma Subjects who have progressed on or after a Trastuzumab – Containing Regimen (DESTINY-Gastric04)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- An Open Label Phase 2 study to evaluate the Safety and Efficacy of MTL-CEPBA Administered with Sorafenib in Participants with Hepatocellular Carcinoma(HCC) and Hepatitis B or Hepatitis C virus
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A real world study on Lenvatinib in HCC patients in an Academic Cancer Centre
Role: Primary Investigator
Place : National Cancer Institute Singapore
GU cancers Clinical Trials
- A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects with Metastatic Castrate Resistant Prostate Cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- Randomized, Open-Label, Phase 3 study of Acapatamab vs standard of Care in Metastatic Castrate-Resistant Prostate Cancer(CAPTIVATE)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Randomized Open-Label Phase III study of Sacituzumab Govitecan versus Treatment of Physician’s Choice in Subjects with metastatic Locally Advanced Unresectable Urothelial Cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Randomized Phase 3 study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy alone in Cisplatin-Ineligible Participants with Muscle Invasive Bladder Cancer (Keynote 905/EV 303)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A randomized, Double-Blind, Controlled Phase 3 study of Cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in previously untreated advanced or metastatic Renal Cell Carcinoma of Intermediate or poor risk
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A randomized, open label, multicenter seamless Phase 2/3 study to evaluate the efficacy and safety of rogaritinib ( BAY 1163877) compared with chemotherapy in patients with FGFRpositive locally advanced metastatic urothelial carcinoma who have received prior platinum containing chemotherapy
Role : Co-Investigator
Place : National Cancer Institute Singapore
Gynaecological Cancers Clinical trials
- A randomized, Open-Label, Phase 3 trial of Tisotumab Vedotin vs investigator’s choice of chemotherapy in second or third line recurrent or metastatic Cervical Cancer
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A Phase III, Multi-center, randomized (1:1), open label, active controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agents cytotoxic chemotherapy in participants with no germline BRCA mutation detected , platinum-resistant or referactory, high-grade serous ovarian cancer (EPIK-O)
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A single-arm phase II trial to evaluate the safety and efficacy of the antibody-drug conjugate SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma who previously progressed on or after first line platinum-based chemotherapy
Role : Co-Investigator
Place : National Cancer Institute Singapore
- A randomized, multicentre, Double-blind, Placebo-controlled, Phase II Study of First-Line Carboplatin and Paclitaxel in Combination with Druvalumab, followed by maintenance Durvalumab with or without Olaparib in patients with newly diagnosed advanced or Recurrent Endometrial Cancer ( DUO-E)
Role : Co-Investigator
Place : National Cancer Institute Singapore
